Title : A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3).

Pub. Date : 2021 May 13

PMID : 33986418






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Two of these broad-spectrum PRL inhibitors, Salirasib and Candesartan, blocked PRL-3-induced migration in human embryonic kidney cells with no impact on cell viability. farnesylthiosalicylic acid protein tyrosine phosphatase 4A3 Homo sapiens
2 In silico modeling revealed that Salirasib binds a putative allosteric site near the WPD loop of PRL-3, while Candesartan binds a potentially novel targetable site adjacent to the CX5R motif. farnesylthiosalicylic acid protein tyrosine phosphatase 4A3 Homo sapiens